Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Fornaro

Showing results (1-10 of 142) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|December 7, 2017
Neoadjuvant chemotherapy in oesophageal adenocarcinomaLorenzo Fornaro, Giuseppe Aprile
Epigenomics|March 4, 2014
Genome-epigenome interactions: the Polycomb paradoxFrancesco Crea, Lorenzo Fornaro
Nature|July 16, 2024
Abandoning randomized controlled trials won't help cancer treatmentLorenzo Fornaro, Francesco Crea
The New England Journal of Medicine|March 21, 2019
FOLFIRINOX Adjuvant Therapy for Pancreatic CancerCaterina Vivaldi, Lorenzo Fornaro, Enrico Vasile
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric CancerLorenzo Fornaro, Mario Scartozzi, Giuseppe Aprile
Translational Gastroenterology and Hepatology|March 10, 2017
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancerCaterina Vivaldi, Alfredo Falcone, Lorenzo Fornaro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Apatinib in Advanced Gastric Cancer: A Doubtful Step ForwardLorenzo Fornaro, Enrico Vasile, Alfredo Falcone
Frontiers in Oncology|December 18, 2025
Editorial: Innovative approaches to cholangiocarcinoma: diagnosis, treatment, and multidisciplinary careKarol Rawicz-Pruszyński, Piero Boraschi, Lorenzo Fornaro
Epigenomics|September 7, 2017
Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancerPier-Luc Clermont, Lorenzo Fornaro, Francesco Crea
The Oncologist|September 24, 2020
In ReplyCaterina Vivaldi, Lorenzo Fornaro, Clara Ugolini, et al.
Pageof 15

Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|December 7, 2017
Neoadjuvant chemotherapy in oesophageal adenocarcinomaLorenzo Fornaro, Giuseppe Aprile
Epigenomics|March 4, 2014
Genome-epigenome interactions: the Polycomb paradoxFrancesco Crea, Lorenzo Fornaro
Nature|July 16, 2024
Abandoning randomized controlled trials won't help cancer treatmentLorenzo Fornaro, Francesco Crea
The New England Journal of Medicine|March 21, 2019
FOLFIRINOX Adjuvant Therapy for Pancreatic CancerCaterina Vivaldi, Lorenzo Fornaro, Enrico Vasile
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric CancerLorenzo Fornaro, Mario Scartozzi, Giuseppe Aprile
Translational Gastroenterology and Hepatology|March 10, 2017
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancerCaterina Vivaldi, Alfredo Falcone, Lorenzo Fornaro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Apatinib in Advanced Gastric Cancer: A Doubtful Step ForwardLorenzo Fornaro, Enrico Vasile, Alfredo Falcone
Frontiers in Oncology|December 18, 2025
Editorial: Innovative approaches to cholangiocarcinoma: diagnosis, treatment, and multidisciplinary careKarol Rawicz-Pruszyński, Piero Boraschi, Lorenzo Fornaro
Epigenomics|September 7, 2017
Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancerPier-Luc Clermont, Lorenzo Fornaro, Francesco Crea
The Oncologist|September 24, 2020
In ReplyCaterina Vivaldi, Lorenzo Fornaro, Clara Ugolini, et al.
Pageof 15